Total Payments
$1.4M
2024 Payments
$121,054
Companies
47
Transactions
2,106
Medicare Patients
1,538
Medicare Billing
$171,557
Payment Breakdown by Category
Other$1.1M (79.5%)
Travel$131,236 (9.2%)
Consulting$74,685 (5.2%)
Food & Beverage$45,534 (3.2%)
Royalty/License$41,069 (2.9%)
Education$216.87 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 722 | 78.3% |
| Travel and Lodging | $131,236 | 428 | 9.2% |
| Consulting Fee | $74,685 | 49 | 5.2% |
| Food and Beverage | $45,534 | 879 | 3.2% |
| Royalty or License | $41,069 | 2 | 2.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $9,500 | 4 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,900 | 3 | 0.3% |
| Acquisitions | $3,689 | 2 | 0.3% |
| Honoraria | $730.00 | 3 | 0.1% |
| Education | $216.87 | 14 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $546,249 | 582 | $0 (2024) |
| Lilly USA, LLC | $292,239 | 479 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $202,671 | 268 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $111,313 | 190 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $54,049 | 84 | $0 (2018) |
| Medtronic MiniMed, Inc. | $43,634 | 30 | $0 (2020) |
| Abbott Laboratories | $42,193 | 66 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $39,019 | 78 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $26,406 | 31 | $0 (2023) |
| Insulet Corporation | $13,820 | 73 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121,054 | 152 | Lilly USA, LLC ($52,687) |
| 2023 | $139,787 | 199 | Lilly USA, LLC ($66,020) |
| 2022 | $174,385 | 224 | Lilly USA, LLC ($87,257) |
| 2021 | $156,150 | 195 | Novo Nordisk Inc ($91,564) |
| 2020 | $172,468 | 165 | Novo Nordisk Inc ($76,985) |
| 2019 | $179,389 | 248 | Novo Nordisk Inc ($89,920) |
| 2018 | $205,731 | 325 | Novo Nordisk Inc ($82,602) |
| 2017 | $280,338 | 598 | Novo Nordisk Inc ($93,717) |
All Payment Transactions
2,106 individual payment records from CMS Open Payments — Page 1 of 85
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: Diabetes | ||||||
| 12/09/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | Cash or cash equivalent | $124.62 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | Cash or cash equivalent | $9.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | Cash or cash equivalent | $7.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | Amgen Inc. | TEPEZZA (Biological) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,502.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/03/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $417.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/02/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,502.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/02/2024 | Amgen Inc. | TEPEZZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $417.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $146.94 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/20/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $147.22 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/20/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $110.93 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/18/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,437.50 | General |
| 11/06/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $112.00 | General |
| 11/06/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $35.14 | General |
| 10/23/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,251.00 | General |
| 10/22/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $2,085.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/22/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,251.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/21/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Diabetes | ||||||
| 10/21/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $83.51 | General |
| Category: Insulin Pump | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 338 | 512 | $190,762 | $39,224 |
| 2022 | 4 | 353 | 564 | $208,832 | $43,735 |
| 2021 | 7 | 395 | 601 | $214,581 | $50,257 |
| 2020 | 6 | 452 | 584 | $169,954 | $38,342 |
Total Patients
1,538
Total Services
2,261
Medicare Billing
$171,557
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 275 | 435 | $165,790 | $33,557 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $21,440 | $4,765 | 22.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 20 | 34 | $3,532 | $901.47 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 279 | 471 | $178,670 | $37,266 | 20.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $18,666 | $3,970 | 21.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 17 | 20 | $7,680 | $1,626 | 21.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 20 | 36 | $3,816 | $872.09 | 22.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 261 | 442 | $172,228 | $40,560 | 23.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 29 | 29 | $14,732 | $3,400 | 23.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 24 | 26 | $10,166 | $2,578 | 25.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 27 | 29 | $7,962 | $1,321 | 16.6% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 12 | 12 | $4,116 | $1,108 | 26.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 23 | 41 | $4,387 | $1,059 | 24.1% |
| 99421 | Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | Office | 2021 | 19 | 22 | $990.00 | $230.09 | 23.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 249 | 360 | $118,080 | $24,802 | 21.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 88 | 102 | $20,740 | $6,046 | 29.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 37 | 37 | $8,241 | $3,007 | 36.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 24 | 24 | $12,000 | $2,049 | 17.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 36 | $8,136 | $1,913 | 23.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 18 | 25 | $2,757 | $525.39 | 19.1% |
About Dr. Damon Tanton, M.D
Dr. Damon Tanton, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1952429615.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Damon Tanton, M.D has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $121,054 received in 2024. These payments were reported across 2,106 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Tanton has provided services to 1,538 Medicare beneficiaries, totaling 2,261 services with total Medicare billing of $171,557. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Orlando, FL
- Active Since 03/27/2007
- Last Updated 09/30/2014
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1952429615
Products in Payments
- JARDIANCE (Drug) $304,701
- Ozempic (Drug) $164,192
- MOUNJARO (Drug) $130,073
- INVOKANA (Drug) $110,549
- RYBELSUS (Drug) $108,531
- Tresiba (Drug) $107,486
- Rybelsus (Drug) $48,235
- Victoza (Drug) $45,079
- InPen (Device) $44,949
- SOLIQUA (Drug) $41,010
- FreeStyle Libre Pro (Device) $41,003
- LYUMJEV (Drug) $34,661
- Kerendia (Drug) $26,406
- STEGLATRO (Drug) $23,190
- Omnipod (Device) $13,820
- TOUJEO (Drug) $12,992
- TEPEZZA (Biological) $11,420
- Xultophy 100/3.6 (Drug) $9,592
- JANUVIA (Drug) $8,312
- GVOKE PFS (Drug) $7,239
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Orlando
Dr. Hanford Yau, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $563,569
Endocrinology, Diabetes & Metabolism $563,569
Dr. Steven Smith, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $435,517
Endocrinology, Diabetes & Metabolism $435,517
Dr. Tina Thethi, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $188,396
Endocrinology, Diabetes & Metabolism $188,396
Dr. Deepa Taneja, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $27,443
Endocrinology, Diabetes & Metabolism $27,443
Dr. Maha Zikra, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $26,852
Endocrinology, Diabetes & Metabolism $26,852
Dr. Wendy Huhn, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,266
Endocrinology, Diabetes & Metabolism $17,266